Pelthos Therapeutics Inc. 8-K

What Happened
Pelthos Therapeutics Inc. announced its financial results for the three months ended March 31, 2026 and provided an update on company operations in a press release issued May 14, 2026. The press release summarizing the quarterly results was furnished as Exhibit 99.1 to the Form 8-K; a company presentation was furnished as Exhibit 99.2. The report was signed by John M. Gay, Chief Financial Officer.

Key Details

• Filing date: May 14, 2026 (Form 8-K).
• Period covered: three months ended March 31, 2026 (Q1 2026).
• Press release summarizing quarterly results and operational update furnished as Exhibit 99.1.
• Company presentation furnished as Exhibit 99.2; Inline XBRL cover page included as Exhibit 104.
• Disclosure made under Item 2.02 (results of operations) and Item 7.01 (Regulation FD disclosure).

Why It Matters
This 8-K provides Pelthos’s latest quarterly results and an operational update, which contain the company’s reported earnings, revenue, and other financial measures that investors use to assess performance. Because the press release and presentation were furnished under Regulation FD, the information was broadly disclosed to the market; investors should review the Exhibits (99.1 and 99.2) for the detailed figures and management commentary before making investment decisions.